Non-ownership Filings
| Fixed-duration Calquence recommended in EU for CLL | Apr. 29, 2025 |
| Update on CAPItello-280 Phase III trial | Apr. 29, 2025 |
| 1st Quarter Results | Apr. 29, 2025 |
| Enhertu combination improved PFS in 1L HER2+ mBC | Apr. 22, 2025 |
| Result of AGM | Apr. 11, 2025 |
| Imfinzi approved in EU for AEGEAN | Apr. 04, 2025 |
| Enhertu approved in EU in post-ET breast cancer | Apr. 04, 2025 |
Ownership Update Filings
| Holding(s) in Company | Mar. 12, 2025 |
| Director/PDMR Shareholding | Mar. 07, 2025 |
| Director/PDMR Shareholding | Mar. 06, 2025 |
| Director/PDMR Shareholding | Mar. 05, 2025 |
| Holding(s) in Company | Feb. 18, 2025 |
| Director/PDMR Shareholding | Nov. 20, 2024 |
| Director/PDMR Shareholding | Nov. 15, 2024 |